Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Michelle H YoonDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0009-0001-0223-9942
Peter H CulvinerDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Mariana Pereira MoraesDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
Hidetomi NittaDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
Nguyen Thuy Thuong ThuongOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Sarah M FortuneDepartment of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-7565-9975
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-2236-1424
Funding
Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUM1AI179699 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kelly E. Dooley, ERIC L NUERMBERGER · 2024 to 2026
$22.2M
Surviving evolution: Short-term adaptations for fitnessP01AI143575 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JAMES C SACCHETTINI · 2020 to 2026
$18.2M
Gerome Wide Association Study of Bacterial Determinants of Clinical Response in TuberculosisU19AI142793 · NIAID · HARVARD MEDICAL SCHOOL · PI MURRAY, MEGAN B · 2019 to 2023
$14.6M
Dissecting virulence gene regulatory pathways in M. tuberculosis clinical isolatesF32AI174653 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Peter H Culviner · 2024 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Strain diversity drives heterogeneous responses to tuberculosis combination therapy. · full record | OpenQuestion